| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
CytoMed Therapeutics Ltd
13D/A
GDTC · Y1R80M106
|
25.2% |
10/16/2026
Event 10/12/2026
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.